UK drug discovery model must ‘break and change’

A report on the state of drug discovery in the UK has said that failure rates are too high, and called for sweeping changes to the current bench-to-bedside model. It said there needed to be a more joined-up approach among industry, academia and public bodies such as the NHS that can ensure access to patient data, as well as and new ‘humanised’ technologies for identifying targets.